Hims & Hers Health, Inc. announced on March 26 2026 that it will now offer a full range of Novo Nordisk’s FDA‑approved GLP‑1 medications, including Wegovy injections and oral pills, as well as Ozempic pens, to eligible customers.
The new lineup includes Wegovy injection pens in strengths from 0.25 mg to 2.4 mg, an upcoming 7.2 mg dose, and oral Wegovy tablets in 1.5 mg, 4 mg, 9 mg and 25 mg. Ozempic pens, approved for type 2 diabetes, will also be available for weight‑loss treatment under clinical judgment.
This move marks a strategic shift away from the company’s previous reliance on compounded GLP‑1 formulations. By partnering with Novo Nordisk, Hims & Hers reduces regulatory risk, secures a stable supply chain, and aligns its product mix with industry standards, positioning it to compete more directly with other telehealth and pharmacy platforms that already offer branded weight‑loss therapies.
Financially, Hims & Hers reported $2.35 billion in revenue for 2025, a 59% year‑over‑year increase, and $617.8 million in Q4 2025 revenue, up 28.4% from the prior year. The company’s gross margin fell to 74% from 79% in 2024, reflecting the lower margin profile of branded drugs compared to compounded products. Full‑year 2026 revenue guidance is $2.7 billion to $2.9 billion, indicating continued growth expectations despite margin compression.
Management emphasized the strategic importance of the partnership. CEO Andrew Dudum said, "Today we're taking an important next step toward building a better model of healthcare that works for everyday people," while SVP Weight Management Craig Primack noted that the FDA‑approved medications will help more patients achieve lasting health. Novo Nordisk President and CEO Mike Doustdar added, "This agreement with Hims & Hers is a meaningful win for patients in the United States. By expanding access through leading telehealth providers, we are helping to connect more people with our FDA‑approved medicines."
The partnership also resolved a legal dispute: Novo Nordisk dropped its lawsuit against Hims & Hers, removing a significant regulatory threat. Analysts and investors viewed the de‑risking of the supply chain and the alignment with a global pharmaceutical leader as key drivers of the positive market reaction.
In summary, the expansion into FDA‑approved GLP‑1 products positions Hims & Hers for sustained growth in the high‑demand weight‑loss market, while the shift to branded drugs is expected to compress margins. The partnership signals a strategic pivot toward a more compliant, scalable business model that could enhance long‑term competitiveness.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.